Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

January 24, 2025
PRESS RELEASE REGULATED INFORMATION 24 January 2025, 19:30 CET Conversion of EUR 0.53 million under the Sensinnovat 2020 loan,  EUR 1.28 million under the 2024 convertible loan with various shareholders, and EUR 2.68 million under the Kreos 2022 loan into equity, reduces net debt by EUR 4.50 million Ghent, Belgium, 24 January 2025 – Sequana...
Read More

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES